• U.S. has deadliest day of the coronavirus pandemic since May
    The Week

    U.S. has deadliest day of the coronavirus pandemic since May

    Nearly 2,100 COVID-19 deaths were recorded in the United States on Tuesday, The Washington Post says — the highest daily number since May 6, when 2,611 deaths were reported.Nine states — Alaska, Indiana, Maine, Missouri, North Dakota, Ohio, Oregon, Washington, and Wisconsin — all reported a record number of fatalities.More than 85,000 people are hospitalized with the virus across the United States, setting a new record for the 14th day in a row, the COVID Tracking Project reports. The Department of Health and Human Services released a report stating that there are more than 1,000 U.S. hospitals that are "critically short on staff," CBS News reports, and the death rate is climbing so fast in El Paso that there are 14 mobile morgues now stationed in the city.Dr. Hassan Taha with Stormont Vail Health in Topeka, Kansas, told CBS News that there are more than 100 coronavirus patients at the hospital, which has reached capacity. "What is worrying to me is two weeks from now Thanksgiving and having a lot of cases that will end up coming to us, or to other hospitals, and there's no beds," Taha said.More stories from theweek.com Obama the pretender People are skeptical that Ivanka Trump and Jared Kushner will be able to easily slip back into NYC society Biden is giving the left nothing for their investment

  • Black Friday Refrigerator Deals (2020): Best Full Size, Mini, Retro & More Fridge Deals Researched by Save Bubble

    Black Friday Refrigerator Deals (2020): Best Full Size, Mini, Retro & More Fridge Deals Researched by Save Bubble

    The top refrigerator deals for Black Friday 2020, including all the latest counter depth, retro & more fridge deals Black Friday refrigerator deals for 2020 are underway. Find the top savings on Frigidaire, LG, Samsung and more. Shop the best deals in the list below.Best Refrigerator Deals: * Save up to 35% on a wide range of fridges from top brands including Arctic King, Frigidaire, Galanz & more at Walmart \- save on a wide range of mini, compact, single, full-size, wine fridges & refrigerators * Save up to 31% on top-rated fridge freezers, refrigerators & wine fridges at Amazon \- check the latest deals on refrigerators from trusted brands including Samsung & Smeg * Save up to 25% on fridges by LG, Magic Chef, Smeg & more at Overstock.com \- check live prices on mini, double drawer, and commercial fridges * Save up to 33% off on refrigerators from Whirlpool, Frigidaire, Sunbeam, and more at Target  - click the link for the latest deals on mini, full size, and counter depth fridge models     * Save up to $900 on best-selling fridges by Samsung, LG, GE & more at Abt.com \- check the latest savings on side-by-side, top freezer, French door, and compact refrigerators * Save up to 66% on mini fridges by brands like Galanz, Frigidaire Arctic King & more at Walmart \- check live prices on single door and two door mini fridges * Save up to $970 on a wide range of refrigerators at KitchenAid.com \- check the latest deals on undercounter, side-by-side, and French door refrigerators * Save up to $310 on counter depth refrigerators at KitchenAid.com * Save up to 25% on top-rated mini fridges at Amazon \- check the latest deals on mini fridges from BLACK+DECKER, Frigidaire, Galanz, and more * Save up to $400 on a wide range of full size fridges at Walmart \- check the latest savings on full size fridges from Frigidaire, Whirlpool, Summit, Danby, and more * Save up to $900 on full size fridges from Galanz, Frigidaire, and Avanti at Amazon \- check live prices on single door and two door full size fridgesInterested in more deals? Click here to check out the full selection of active deals at Walmart’s Black Friday sale and click here to shop Amazon’s latest Black Friday deals. Save Bubble earns commissions from purchases made using the links provided.About Save Bubble: Save Bubble round-up the latest online sales news. As an Amazon Associate and affiliate Save Bubble earns from qualifying purchases.Contact: Andy Mathews (andy@nicelynetwork.com)

  • Basilea reports acceptance for regulatory review of Pfizer’s marketing authorization application for antifungal isavuconazole (Cresemba®) in invasive aspergillosis in China

    Basilea reports acceptance for regulatory review of Pfizer’s marketing authorization application for antifungal isavuconazole (Cresemba®) in invasive aspergillosis in China

    * Second indication under review following mucormycosis Basel, Switzerland, November 25, 2020Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the marketing authorization application (MAA) for the antifungal isavuconazole (Cresemba®) for the treatment of adult patients with invasive aspergillosis, which was submitted by Basilea’s license partner Pfizer Inc. (NYSE: PFE, “Pfizer”), has been accepted for regulatory review by the Center for Drug Evaluation at the National Medical Products Administration (NMPA) of China. In August 2020, Basilea had announced that an MAA for Cresemba for the treatment of mucormycosis was accepted for review by the NMPA.David Veitch, Chief Executive Officer, said: “Invasive aspergillosis and mucormycosis are the two most frequent forms of invasive mold infections and important causes of morbidity and mortality in patients with hematologic malignancies undergoing intensive chemotherapy regimens. China is commercially a very important market for Cresemba, accounting for more than 15 percent of the global market for newer antifungals. We are therefore very pleased with the progress Pfizer is making in China. The acceptance of the isavuconazole marketing authorization applications for regulatory review is an important milestone in bringing Cresemba to the Chinese market and addressing the unmet medical needs of patients suffering from invasive mold infections.”In November 2017, Basilea and Pfizer extended their existing license agreement for Europe (excluding the Nordics), Russia, Turkey and Israel, to include China, including Hong Kong and Macao, and sixteen countries in the Asia Pacific region. Under the agreement with Pfizer, Basilea is still eligible for regulatory and sales milestone payments of up to approximately USD 630 million, in addition to receiving mid-teen royalties on sales.Cresemba has been approved in more than 50 countries to date and is currently marketed in 48 countries, including the United States, most EU member states and several additional countries inside and outside of Europe. For the twelve-month period to the end of June 2020, total "in-market" sales of Cresemba amounted to USD 230 million, a 30 percent growth year-on-year.1About Cresemba (isavuconazole)Isavuconazole is an intravenous (i.v.) and oral azole antifungal, commercialized under the trade name Cresemba. In the 27 European Union member states, as well as in Iceland, Liechtenstein, Norway and the U.K., isavuconazole is approved for the treatment of adult patients with invasive aspergillosis and for the treatment of adult patients with mucormycosis for whom amphotericin B is inappropriate.2 Cresemba is also approved in the United States and several additional countries in Europe and beyond.3 It has orphan drug designation in the U.S., Europe and Australia for its approved indications. Basilea has entered into several license and distribution agreements for isavuconazole covering the United States, Europe, China, Japan, Latin America, Asia-Pacific, the Middle East and North Africa region, Canada, Russia, Turkey and Israel.About BasileaBasilea Pharmaceutica Ltd. is a commercial-stage biopharmaceutical company, focused on the development of products that address the medical challenges in the therapeutic areas of oncology and infectious diseases. With two commercialized drugs, the company is committed to discovering, developing and commercializing innovative pharmaceutical products to meet the medical needs of patients with serious and life-threatening conditions. Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN). Additional information can be found at Basilea's website www.basilea.com.DisclaimerThis communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning Basilea Pharmaceutica Ltd. and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.For further information, please contact:Peer Nils Schröder, PhD Head of Corporate Communications & Investor Relations Phone+41 61 606 1102 E-mailmedia_relations@basilea.com investor_relations@basilea.com  This press release can be downloaded from www.basilea.com.References 1. IQVIA, June 2020. In-market sales reported as moving annual total (MAT) in U.S. Dollar corrected for currency fluctuations. 2. European Public Assessment Report (EPAR) Cresemba: http://www.ema.europa.eu [Accessed: November 24, 2020] 3. The registration status and approved indications may vary from country to country. Attachment * Press release (PDF)